<DOC>
	<DOCNO>NCT00003397</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation plus combination chemotherapy rituximab treat patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Plus Combination Chemotherapy Monoclonal Antibody Therapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate 1 2 year event free survival patient poor prognosis , relapse refractory intermediate high grade B-cell non-Hodgkin 's lymphoma receive high dose carmustine melphalan plus gemcitabine follow rituximab ( IDEC-C2B8 monoclonal antibody ; anti-CD20 monoclonal antibody ) plus sargramostim consolidation chemotherapy alternate dexamethasone/cyclophosphamide/ etoposide/cisplatin plus gemcitabine paclitaxel/cisplatin compare figure historical control population . II . Evaluate ability posttransplant rituximab therapy combination sargramostim ( GM-CSF ) control treat residual lymphoma remain high dose therapy patient . III . Evaluate quality life parameter assess risk secondary malignancy follow treatment regimen patient . OUTLINE : Patients receive high dose gemcitabine IV 100 minute day -5 approximately 6 hour carmustine IV 2 hour day -2 . On day -1 , patient receive melphalan IV 20 minute follow 24 hour later ( day 0 ) peripheral blood stem cell transplantation . Patients receive sargramostim ( GM-CSF ) subcutaneously begin day 4 granulocyte count great 1,000/mm3 2 consecutive day . At week 5-8 posttransplant , patient receive rituximab ( IDEC-C2B8 monoclonal antibody ; anti-CD20 monoclonal antibody ) IV 3-4 hour weekly . Prior rituximab treatment week 4 posttransplant , patient receive sargramostim ( GM-CSF ) subcutaneously 3 time week continue rituximab therapy . At approximately 3 9 month posttransplant , patient receive dexamethasone orally every day day 1-4 , cyclophosphamide , etoposide , cisplatin continuous infusion 4 day ( day 1-4 ) , gemcitabine IV 100 minute day 1 5 . At approximately 6 12 month posttransplant , patient receive paclitaxel IV 6 hour day 2 cisplatin IV 24 hour day 3 . Patients follow least every 6 week 3 month death . PROJECTED ACCRUAL : An estimated 25 patient per year accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate high grade Bcell nonHodgkin 's lymphoma meet one follow criterion : Relapsed progress follow least 1 course standard therapy Developed low grade lymphoma regardless remission status In first complete response 3 follow pretreatment criterion meet time original diagnosis : Stage III/IV disease Two extranodal site disease Lactate dehydrogenase great 1.2 time normal Performance status 24 ( time diagnosis ) Dimension large tumor least 10 cm No myelodysplasia A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 75 Performance status : See Disease Characteristics ECOG 02 ( ECOG 34 acceptable base solely pain ) Life expectancy : Not specify Hematopoietic : CD34 cell least 1,000/g Hepatic : See Disease Characteristics Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal No active chronic hepatitis liver cirrhosis Renal : Creatinine great 3.0 mg/dL Cardiovascular : No evidence clinically significant functional impairment Left ventricular ejection fraction least 45 % Patients low ejection fraction may include formal cardiological evaluation reveals evidence clinically significant functional impairment Pulmonary : FEV1 , FVC , DLCO least 50 % predict If unable complete pulmonary function test due bone pain fracture , must high resolution CT scan chest acceptable blood arterial gas define PO2 great 70 Other : HIV negative No active infection unresponsive intravenous antibiotic Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>